Clinical Trial Shows Promise for Increasing Lung Transplant Patients’ Life Expectancy

Results of a first-in-humans trial presented at AATS 99th Annual Meeting indicates the safety of a novel treatment for ischemia reperfusion injury where none has existed to-date.


Newswise — TORONTO – May 5, 2019 – A new study, presented today at the American Association for Thoracic Surgery’s 99thAnnual Meeting, shows that a potential treatment for ischemia- reperfusion injury is safe for humans.  Building upon three decades of preclinical animal studies, this NIH-funded trial demonstrated, for the first time, the safety of Regadenoson (an adenosine 2A receptor agonist) in human lung transplant patients. 

Ischemia-reperfusion injury is a major source of morbidity and mortality in lung transplant patients, and contributes to the less than optimal survival rates in lung transplant recipients.  Adenosine 2AR agonists like Regadenoson offer a potentially novel treatment for this common inflammatory complication where none exists today.  Researchers found no dose limiting toxicities in the non-randomized trial and no 30-day mortality. 

The TCV lab at University of Virginia, under the direction of Dr. Irving Kron, has spent three decades studying the efficacy of A2AR agonists for lung transplant in rodents and large animals. 

In humans, Regadenoson, (LexiscanTM), is clinically approved as a bolus for myocardial imaging, but its safety profile in the high risk lung transplant population as an infusion had not been established. This clinical trial was designed to assess the safety of regadenoson in human lung transplant recipients as a prequel to an efficacy trial.

“It is gratifying to see this research move from bench to bedside, with decades of work culminating in a clinical trial,” said Senior Author, Dr. Christine Lau, Professor of Surgery in the Division of Thoracic & Cardiovascular Surgery at the University of Virginia. “As the field of lung transplants evolves rapidly, we continue to see ischemia-reperfusion injury, making the potential of a new treatment an exciting development.”

With safety established, the next step for testing efficacy is a multi-institutional, randomized trial.  Additionally, because the treatment appears effective whether the drug is given to the donor lung or the recipient, future trials will use ex-vivolung profusion to administer the drug only to the donor lung, eliminating any risk to the patient.

Presenting author Dr. Joshua A. Boys, MD explained, “This treatment has the potential to be the next big thing in the world of lung transplants. With further study, this can quickly move from a quality of life improvement therapy to one that greatly improves survival for the long term.”

 # # #

Notes for Editors: 

First in Human, Use of Regadenoson: An Adenosine 2A Receptor Agonist in Lung Transplant Recipients Christine L. Lau1, Jennifer V Phillips1, Michael J Cosner1, Mark R Conaway1, Gina R Petroni1, A. Sasha Krupnick1, Yunge Zhao1, Joel Linden2, Irving L Kron3 1University of Virginia, Charlottesville, VA;2La Jolla Institute for Immunology, La Jolla, CA;3University of Arizona Health Sciences, Tucson, AZ

Presented by Joshua A. Boys, MD, Sunday, May 5, 2019 at the AATS 99th Annual Meeting.

 ABOUT THE AMERICAN ASSOCIATION FOR THORACIC SURGERY (AATS)

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premiere association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit www.aats.org to learn more. 

SEE ORIGINAL STUDY

Chat now!
2.49347